July 11, 2008-- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Abbreviated New Drug Application (ANDA) for a generic version of Copaxone (glatiramer acetate injection), submitted by Sandoz Inc., Momenta’s development and commercialization partner for this product.
The details can be read here.
No comments:
Post a Comment